DE69936784D1 - Behandlung von gebärmutterhalskrebs - Google Patents
Behandlung von gebärmutterhalskrebsInfo
- Publication number
- DE69936784D1 DE69936784D1 DE69936784T DE69936784T DE69936784D1 DE 69936784 D1 DE69936784 D1 DE 69936784D1 DE 69936784 T DE69936784 T DE 69936784T DE 69936784 T DE69936784 T DE 69936784T DE 69936784 D1 DE69936784 D1 DE 69936784D1
- Authority
- DE
- Germany
- Prior art keywords
- nucleic acid
- acid molecule
- treatment
- hpv
- cervical cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 235000016709 nutrition Nutrition 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 2
- 241000701806 Human papillomavirus Species 0.000 abstract 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 2
- 201000010881 cervical cancer Diseases 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 241000341655 Human papillomavirus type 16 Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0263—Measuring blood flow using NMR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- High Energy & Nuclear Physics (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9929198P | 1998-09-04 | 1998-09-04 | |
US99291P | 1998-09-04 | ||
PCT/CA1999/000807 WO2000014244A2 (en) | 1998-09-04 | 1999-09-03 | Treatment of cervical cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69936784D1 true DE69936784D1 (de) | 2007-09-20 |
DE69936784T2 DE69936784T2 (de) | 2008-04-30 |
Family
ID=22274255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69936784T Expired - Lifetime DE69936784T2 (de) | 1998-09-04 | 1999-09-03 | Behandlung von gebärmutterhalskrebs |
Country Status (14)
Country | Link |
---|---|
US (1) | US6235523B1 (de) |
EP (2) | EP1728865A1 (de) |
JP (2) | JP2002524078A (de) |
AT (1) | ATE369428T1 (de) |
AU (1) | AU766403C (de) |
CA (1) | CA2342289C (de) |
CY (1) | CY1107762T1 (de) |
DE (1) | DE69936784T2 (de) |
DK (1) | DK1108035T3 (de) |
ES (1) | ES2291039T3 (de) |
NZ (1) | NZ510488A (de) |
PT (1) | PT1108035E (de) |
SI (1) | SI1108035T1 (de) |
WO (1) | WO2000014244A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
US8128922B2 (en) * | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
EP2278022A3 (de) * | 1999-11-01 | 2011-05-18 | Novartis Vaccines and Diagnostics, Inc. | Expressionsvektoren, Transfektionssysteme und Verfahren zu deren Verwendung |
PL365385A1 (en) * | 2000-07-21 | 2005-01-10 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
AU2001278117A1 (en) * | 2000-08-03 | 2002-02-18 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
DE10055545A1 (de) * | 2000-11-09 | 2002-07-25 | Deutsches Krebsforsch | Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen |
US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
FR2839072A1 (fr) * | 2002-04-24 | 2003-10-31 | Neovacs | Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation |
AU2003221650A1 (en) * | 2002-04-24 | 2003-11-10 | Universite Libre De Bruxelles | Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process |
WO2004002416A2 (en) | 2002-06-26 | 2004-01-08 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
AU2003284239B2 (en) * | 2002-10-21 | 2008-08-21 | Eisai Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
WO2004098526A2 (en) * | 2003-05-05 | 2004-11-18 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
DE602005022458D1 (de) | 2004-09-10 | 2010-09-02 | Asahi Glass Co Ltd | Impfstoff gegen humanes papillomavirus zur oralen verabreichung |
EP1819835B1 (de) | 2004-12-08 | 2010-08-04 | Gen-Probe Incorporated | Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus |
EP3072522B1 (de) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Behandlungen und verfahren mit anti-kir-kombination |
WO2006073970A2 (en) * | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
CA2595726A1 (en) * | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
WO2008024844A2 (en) * | 2006-08-22 | 2008-02-28 | The Johns Hopkins University | Anticancer combination therapies |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
WO2009127988A1 (en) * | 2008-04-16 | 2009-10-22 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
US9376727B2 (en) | 2010-05-25 | 2016-06-28 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically truncated probes |
JP6093696B2 (ja) | 2010-06-09 | 2017-03-08 | ゲンマブ エー/エス | ヒトcd38に対する抗体 |
JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
CN105018525B (zh) * | 2014-08-12 | 2017-06-13 | 广东拓谱康生物科技有限公司 | 携带人乳头瘤病毒16型突变型E7m91抗原基因的重组腺相关病毒载体及其构建方法与应用 |
JP6863907B2 (ja) * | 2018-01-05 | 2021-04-21 | 日本電信電話株式会社 | 演算回路 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744133A (en) * | 1986-08-13 | 1998-04-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor |
GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
AUPN015794A0 (en) * | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
-
1999
- 1999-09-03 CA CA2342289A patent/CA2342289C/en not_active Expired - Fee Related
- 1999-09-03 WO PCT/CA1999/000807 patent/WO2000014244A2/en active IP Right Grant
- 1999-09-03 AT AT99942661T patent/ATE369428T1/de active
- 1999-09-03 DK DK99942661T patent/DK1108035T3/da active
- 1999-09-03 JP JP2000568985A patent/JP2002524078A/ja active Pending
- 1999-09-03 NZ NZ510488A patent/NZ510488A/en not_active IP Right Cessation
- 1999-09-03 ES ES99942661T patent/ES2291039T3/es not_active Expired - Lifetime
- 1999-09-03 PT PT99942661T patent/PT1108035E/pt unknown
- 1999-09-03 EP EP06015673A patent/EP1728865A1/de not_active Withdrawn
- 1999-09-03 US US09/390,027 patent/US6235523B1/en not_active Expired - Lifetime
- 1999-09-03 AU AU56118/99A patent/AU766403C/en not_active Ceased
- 1999-09-03 SI SI9930983T patent/SI1108035T1/sl unknown
- 1999-09-03 EP EP99942661A patent/EP1108035B1/de not_active Expired - Lifetime
- 1999-09-03 DE DE69936784T patent/DE69936784T2/de not_active Expired - Lifetime
-
2003
- 2003-12-18 JP JP2003421029A patent/JP4205572B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-12 CY CY20071101318T patent/CY1107762T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
NZ510488A (en) | 2003-07-25 |
EP1728865A1 (de) | 2006-12-06 |
DE69936784T2 (de) | 2008-04-30 |
ES2291039T3 (es) | 2008-02-16 |
SI1108035T1 (sl) | 2007-12-31 |
DK1108035T3 (da) | 2007-09-24 |
CA2342289A1 (en) | 2000-03-16 |
WO2000014244A3 (en) | 2000-06-02 |
CA2342289C (en) | 2012-07-24 |
EP1108035B1 (de) | 2007-08-08 |
JP2002524078A (ja) | 2002-08-06 |
WO2000014244A2 (en) | 2000-03-16 |
JP4205572B2 (ja) | 2009-01-07 |
AU766403C (en) | 2004-05-27 |
PT1108035E (pt) | 2007-11-20 |
CY1107762T1 (el) | 2013-06-19 |
US6235523B1 (en) | 2001-05-22 |
EP1108035A2 (de) | 2001-06-20 |
AU766403B2 (en) | 2003-10-16 |
AU5611899A (en) | 2000-03-27 |
JP2004121263A (ja) | 2004-04-22 |
ATE369428T1 (de) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69936784D1 (de) | Behandlung von gebärmutterhalskrebs | |
BR9814487A (pt) | "vacina" | |
ATE267211T1 (de) | Impfstoff gegen hpv | |
FI875082A0 (fi) | Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner. | |
NO20013701L (no) | HER-2/neu-fusjonsproteiner | |
WO2000075336A3 (fr) | Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination | |
ATE267258T1 (de) | Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren | |
DE69811087T2 (de) | Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine | |
UA85536C2 (en) | Viral antigens | |
HUP9801608A2 (hu) | A 11. típusú humán papillomavírusból származó L1-fehérjét kódoló szintetikus HPV6/11-L1-hibrid-DNS | |
BR0316158A (pt) | Vacina de vetor adenoviral | |
AU1013701A (en) | Modified gp100 and uses thereof | |
CA2042236A1 (en) | Seroreactive epitopes on proteins of human papillomavirus (hpv) 18 | |
KR970705408A (ko) | 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins) | |
DE3585578D1 (de) | Hepatitisoberflaechenantigenpartikelvakzin. | |
WO1997004099A3 (de) | Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen | |
ATE160376T1 (de) | Dna segment des herpesvirus der marek-krankheit, welches für das glykoprotein ge kodiert | |
EP1427443A4 (de) | Vakzine mit papilloma-virus-e-proteinen, die durch einen viralen vektor abgegeben werden | |
WO1998023752A3 (de) | Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen | |
WO2002060390A3 (en) | Induction of immune responses to isoaspartyl-modified antigens | |
WO1998042847A3 (de) | Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung | |
DK0817859T3 (da) | Rekombinante DNA vektorer til Genterapi | |
WO2000014112A3 (de) | Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |